Latest Dilution News

Neurizon Therapeutics reported a $16.6 million loss for FY2025 amid significant progress in its lead neurodegenerative therapy NUZ-001, including regulatory milestones and a global licensing deal. The company is poised to enter a pivotal ALS clinical trial pending FDA clearance.

Integral Diagnostics posts robust FY25 results with strong revenue growth and merger synergies exceeding expectations, setting a confident tone for FY26.

Kelsian Group Limited has announced a fully franked ordinary dividend of AUD 0.095 per share for the six months ending June 2025, accompanied by a Dividend Reinvestment Plan offering shareholders a choice to reinvest.

Tribeca Global Natural Resources Limited announces a fully franked $0.05 final dividend for FY25 alongside amendments to its Dividend Reinvestment Plan designed to protect shareholder value. The company also launches a 10% on-market share buy-back aiming to capitalize on shares trading below net tangible asset backing.

Aurelia Metals Limited has reported a strong turnaround with a $48.9 million net profit for FY25, driven by operational progress at its Federation Mine and the approval of the Great Cobar Project. The company’s strategic focus on base metals growth and sustainability underpins its improved financial and safety performance.

Intelligent Monitoring Group reports robust FY2025 financials, completes a strategic acquisition, and issues new shares following warrant exercises, signaling a confident growth trajectory.

WebBeds reported a 22% rise in Total Transaction Value to nearly $5 billion for FY25, while EBITDA fell 14% amid margin pressures and higher costs. The company is targeting $10 billion TTV by FY30 with improved profitability.

Fortescue Ltd has announced a fully franked ordinary dividend of AUD 0.60 per share for the fiscal year ending June 30, 2025, with a dividend reinvestment plan available to shareholders.

Firebrick Pharma has closed a $1.4 million placement to fund expansion of its Nasodine nasal spray in key international markets and advance new product development.

Cedar Woods Properties Limited has announced a fully franked ordinary dividend of 19 cents per share for the half-year ending June 2025, accompanied by attractive reinvestment and bonus security plans.

Acrow Limited reports a record FY25 with sales up 23%, driven by an 83% jump in its Industrial Access division, now half of group revenue. Despite soft formwork markets, strategic acquisitions and growth initiatives underpin a confident outlook.

Actinogen Medical reports steady progress in its Alzheimer’s and depression drug trials, backed by strong funding and strategic commercial planning. Key interim data from the pivotal XanaMIA trial is expected early next year.